New Results
A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer
Estela González-Gualda, David Macias, Samir Morsli, José Ezequiel Martín, Hui-Ling Ou, Mary Denholm, View ORCID ProfileIoana Olan, Reuben Hoffmann, Mark Dane, Dimitris Veroutis, Guillermo Medrano, Francisca Mulero, Carla P. Martins, Mariano Barbacid, View ORCID ProfileVassilis Gorgoulis, James E. Korkola, Doris M. Rassl, Gary J. Doherty, Robert C. Rintoul, Masashi Narita, View ORCID ProfileDaniel Muñoz-Espín
doi: https://doi.org/10.1101/2022.08.01.502019
Estela González-Gualda
1Early Cancer Institute, Department of Oncology, University of Cambridge. Cambridge, UK
David Macias
1Early Cancer Institute, Department of Oncology, University of Cambridge. Cambridge, UK
Samir Morsli
1Early Cancer Institute, Department of Oncology, University of Cambridge. Cambridge, UK
José Ezequiel Martín
2CMDL, Department of Oncology, SMCL, Department of Medical Genetics, University of Cambridge
Hui-Ling Ou
1Early Cancer Institute, Department of Oncology, University of Cambridge. Cambridge, UK
Mary Denholm
1Early Cancer Institute, Department of Oncology, University of Cambridge. Cambridge, UK
Ioana Olan
3Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK
Reuben Hoffmann
4Department of Biomedical Engineering, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
Mark Dane
4Department of Biomedical Engineering, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
Dimitris Veroutis
5Department of Histology-Embryology, Medical School, National Kapodistrian University of Athens, Greece
Guillermo Medrano
6Molecular Imaging Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Francisca Mulero
6Molecular Imaging Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Carla P. Martins
7Early Oncology TDE, Oncology R&D, AstraZeneca, Cambridge, CB2 0RE, England
Mariano Barbacid
8Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Vassilis Gorgoulis
5Department of Histology-Embryology, Medical School, National Kapodistrian University of Athens, Greece
9Faculty Institute for Cancer Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
10Department of Clinical Molecular Pathology, Medical School, University of Dundee, Dundee, UK
James E. Korkola
4Department of Biomedical Engineering, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
Doris M. Rassl
11Royal Papworth Hospital NHS Foundation Trust. Cambridge Biomedical Campus, Cambridge CB2 0AY, UK
Gary J. Doherty
12Cambridge University Hospitals NHS Foundation Trust, Department of Oncology, Addenbrookés Hospital, Cambridge CB2 0QQ, UK
Robert C. Rintoul
1Early Cancer Institute, Department of Oncology, University of Cambridge. Cambridge, UK
11Royal Papworth Hospital NHS Foundation Trust. Cambridge Biomedical Campus, Cambridge CB2 0AY, UK
13CRUK Cambridge Centre Thoracic Cancer Programme
Masashi Narita
3Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK
Daniel Muñoz-Espín
1Early Cancer Institute, Department of Oncology, University of Cambridge. Cambridge, UK
13CRUK Cambridge Centre Thoracic Cancer Programme
Posted August 03, 2022.
A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer
Estela González-Gualda, David Macias, Samir Morsli, José Ezequiel Martín, Hui-Ling Ou, Mary Denholm, Ioana Olan, Reuben Hoffmann, Mark Dane, Dimitris Veroutis, Guillermo Medrano, Francisca Mulero, Carla P. Martins, Mariano Barbacid, Vassilis Gorgoulis, James E. Korkola, Doris M. Rassl, Gary J. Doherty, Robert C. Rintoul, Masashi Narita, Daniel Muñoz-Espín
bioRxiv 2022.08.01.502019; doi: https://doi.org/10.1101/2022.08.01.502019
A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer
Estela González-Gualda, David Macias, Samir Morsli, José Ezequiel Martín, Hui-Ling Ou, Mary Denholm, Ioana Olan, Reuben Hoffmann, Mark Dane, Dimitris Veroutis, Guillermo Medrano, Francisca Mulero, Carla P. Martins, Mariano Barbacid, Vassilis Gorgoulis, James E. Korkola, Doris M. Rassl, Gary J. Doherty, Robert C. Rintoul, Masashi Narita, Daniel Muñoz-Espín
bioRxiv 2022.08.01.502019; doi: https://doi.org/10.1101/2022.08.01.502019
Subject Area
Subject Areas
- Biochemistry (11718)
- Bioengineering (8724)
- Bioinformatics (29132)
- Biophysics (14936)
- Cancer Biology (12051)
- Cell Biology (17360)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14146)
- Epidemiology (2067)
- Evolutionary Biology (18269)
- Genetics (12223)
- Genomics (16768)
- Immunology (11844)
- Microbiology (28016)
- Molecular Biology (11560)
- Neuroscience (60822)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10401)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)